Waksal snaps up Three Rivers Pharma; Momenta wins enoxaparin method patent;

@FiercePharma: Notorious Names in Biopharma. Report | Follow @FiercePharma

Special Report: Pharma's Biggest Flops

Special Report: Top 10 Phase III Failures of 2010

> Sam Waksal, former CEO of ImClone Systems, whose insider trading scam sent him to prison, says his Kadmon Pharmaceuticals has bought Three Rivers Pharmaceuticals, and that its treatments for hepatitis C, infections and cancer will be the backbone of a new enterprise. Report

> Astellas Pharma is expected to post a lower operating profit for the full year ending March 2011, hurt by goodwill write-offs, the Nikkei business daily said. Report

> The U.S. Patent and Trademark Office (USPTO) has issued Momenta Pharmaceuticals a patent that covers methods of analyzing and processing enoxaparin, the generic form of Sanofi-Aventis' Lovenox, by analyzing chain sequence information. Momenta release | Report

> A three-way initiative between regulatory authorities in the EU, U.S. and Australia on the inspection of facilities making active pharmaceutical ingredients (APIs) is generating "palpable" results, according to a report on its first 18 months. Report

> Taking a direct approach with the FDA is all the rage these days, and now several parents, who formed a non-profit to protest widespread use of Merck's Gardasil vaccine for HPV, have written the agency to demand that approval be rescinded. Report

> Shire announced that Watson Laboratories has asked FDA to approve a generic version of its Intuniv tablet for high blood pressure and ADHD. Shire release | Report

Biotech News

 @FierceBiotech: After FDA's ARNA decision, what's next for obesity drugs? Article | Follow @FierceBiotech

 @JohnCFierce:  PR on the Kadmon/Waksal deal for Three Rivers. Having $200M in investor cash means never having to say you're sorry. News | Follow @JohnCFierce

> Domain leads $23M round for aTyr Pharma. Story 

> Xconomy: Phenomix forced to close shop after partner dumps pact. Article 

> Analysts take on obesity drugs turns grim after lorcaserin CRL. News 

Biotech Research News

> Washington state invests in pharma firm, with eye to ROI. Item 

> Researchers use microarray to attack malaria mosquito. Report 

> Myriad Genetics appeals gene-patent ruling. News

Manufacturing News

> Consent decree trumps prosecution in some cases. Article 

> FDA: Drugmakers should be hands-on in contractor ops. Report 

> KV launches marketing arm as it resumes ops. Story 

> EMA ups Fabrazyme demand despite of short supply. Item

> Even homeopathy attracts counterfeiters. Story

And Finally... Irish authorities are worried about the declining volume of want-ads in the pharma industry there. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.